Is the Internal Jugular Node Dissection without Level V Sufficient in Patients with Papillary Thyroid Carcinoma with Lateral Neck Node Metastasis? by 강상욱 et al.
31https://jes-online.org
ABSTRACT
Purpose: Papillary thyroid carcinoma (PTC) has a high rate of lateral neck node metastases, 
and completeness of surgical resection is an important determinant of outcomes. The 
appropriate extent of therapeutic lateral neck dissection remains controversial. This study aims 
to access the impact of lateral neck node dissection of levels II to V in a large patient series.
Methods: A retrospective review of the clinical charts and hospital records of 778 consecutive 
patients who had metastatic PTC and who underwent unilateral cervical lymph node 
dissection at a single institution between 1999 January and 2009 December.
Results: A total of 489 modified radical neck dissection (MRND) (levels II–V) and 289 
internal jugular node dissection (IJND) (levels II–IV) were performed in 778 patients. There 
were no differences in clinicopathological findings except for the retrieved and metastatic 
lateral lymph nodes (LLNs). The multiple-level lymph node (LN) metastasis was more 
prevalent in the MRND group, and the distribution of metastasis lymph node levels was 
significantly different in both group. The recurrence rate and disease-free survival were 
similar in the 2 groups. In multivariate analysis, female sex, tumor size, and multi-level 
LLN metastasis were independent predictors recurrence. Postoperative complications were 
similar in MRND and IJND group.
Conclusion: IJND achieves favorable postoperative results in PTC with lateral neck node 
metastasis patients, and level V metastasis/recurrence incidence is low. Therefore, the extent 
of lateral neck node dissection, whether IJND or MRND, can be considered for patients 
according to the simultaneous metastasis level and the tumor size.
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INTRODUCTION
The incidence of papillary thyroid carcinoma (PTC), the most common malignancy 
originating from thyroid gland, is increasing worldwide. In Korea, the annual incidence of 
thyroid cancer rose from 6.3 cases per 100,000 in 1999 to 51.1 cases per 100,000 in 2017, 
which represents a 22.4% annual increase over the last 10 years (1).
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PTC has a good prognosis, but it has a high incidence of lymph node (LN) metastasis, occurring 
in 30%–80% in central neck and in 10%–30% in lateral neck (2-5). In cases of lateral lymph 
node metastasis (LNM) from PTC, lateral neck node dissection (LND) for clinically evident 
metastasis is the treatment of choice (6). Since the first description of radical neck dissection 
(RND) in head and neck cancer patients was published by Crile in 1906 (7), a systemic en bloc 
resection of the lymphatics of the neck has been an important modality to control of regional 
metastasis. During the past 100 years, the extent of LND in head and neck cancer has evolved 
from a single, radical operation to a variety of operations that are selected according to the 
extent of the metastatic tumor in the neck and to the location of the primary tumor.
Although American Thyroid Association (ATA) guideline recommended that therapeutic 
lateral neck compartmental LN dissection should be performed for patients with biopsy-
proven metastatic lateral cervical lymphadenopathy (8). LND should include level II, III, 
IV, and V, formal modified radical neck dissection (MRND) has more risk of injury of spinal 
accessory nerve (SAN) and sensory nerve branches such as greater auricular, cervical 
cutaneous, and supraclavicular nerves (9,10). Therefore, controversy remains among 
surgeons about whether it is necessary to dissect level V LNs in all PTC patients with LNM. 
Currently, most surgeons recommend formal MRND, sparing the SAN, internal jugular vein, 
and the sternocleidomastoid muscle (11), while some surgeons support internal jugular 
node dissection (IJND) in low-risk PTC with LNM (level II–IV, but not level V) cautiously to 
decrease complications after neck dissection (12-14). Until now, few comparative studies 
have been done on long-term follow-up outcomes after LND with or without level V LN (15-
17). Hence, in this study, we evaluated and compared the surgical outcomes of IJND without 
level V and MRND in patients with PTC with LNM to determine if the extent of lateral LN 
dissection affected recurrence and survival rates.
MATERIALS AND METHODS
We retrospectively reviewed the medical records of 1,136 consecutive patients with PTC and 
LNM who underwent bilateral total thyroidectomy with central compartment neck dissection 
(CCND) and ipsilateral LND from January 1999 to December 2009 in the Department 
of Surgery, Severance Hospital, Korea. Among these patients, 358 were excluded due to 
insufficient medical records, short follow-up periods with less than 2 years, non-PTC, non-
proven lateral neck node metastasis in the final pathology report, and synchronous distant 
metastasis at the initial diagnosis. We also excluded PTC with bilateral LN metastasis and 
patients who underwent LND due to lateral neck node recurrence after initial bilateral total 
thyroidectomy. Therefore, a total of 778 patients were finally enrolled in the study.
Patients were classified 2 groups as those who had performed formal MRND and IJND, 
retrospectively. The MRND group comprised 489 patients and IJND group 289 patients. The 
indications of IJND were small tumor size, single LLN metastasis, not palpable or suspicious 
metastasis LN in US or CT in level V. We compared the clinicopathological characteristics, surgical 
outcomes, such as operation time, hospital stays, and number of retrieved LNs, postoperative 
complications, recurrence rate and pattern, and disease-free survival (DFS) in the 2 groups.
All patients were diagnosed as having PTC by preoperative ultrasonography (US)-guided fine 
needle aspiration biopsy (FNAB). Staging neck ultrasonography (US) and a neck computed 
tomography (CT) scan were performed to evaluate preoperative clinical stages (18).
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All study subjects had clinically palpable LNNs or a lateral LN suspected of a metastasis by 
preoperative US staging. The LNM was confirmed by FNAB for the node, and thyroglobulin 
(Tg) measurement in the wash-out of needles used for FNAB (19) was performed to 
determine whether the patient needed therapeutic LND. Cervical LN levels were defined 
using the Memorial Sloan Kettering Cancer Center nomenclature, where level I represented 
submental and submandibular group; level II, III and IV represented upper, mid, and lower 
jugular groups, respectively; and level V represented the posterior triangular group (20).
The extent of LN dissection for unilateral MRND routinely performed at our institution 
includes CCND and LND (II, III, IV, and V), whereas the SND procedure included CCND and 
LND (II, III, and IV) without the dissection of level V. During surgery, the cervical LN levels 
present in dissected specimens were classified individually by the supervising surgeon.
After surgery, all patients were treated with levothyroxine to suppress thyroid-stimulating 
hormone. All patients received high-dose (150 mCi) radioactive iodine (RI) therapy without 
a diagnostic 131I whole-body scan in order to avoid a “stunning effect” (i.e., decreased uptake 
by a thyroid remnant of 131I after diagnostic administration of 131I) (21). RI with 100–150 mCi 
was administered 8–12 weeks after TT (demand for RI in Korea delayed RI therapy in some 
cases), when each patient was in hypothyroidism after levothyroxine had been withdrawn 
for 4 weeks and a low-iodine diet had been maintained for 2 weeks. Patients received 
written instructions and were assisted by a dietician. The 131I whole-body scan was taken on 
the second day after RI treatment. We regularly followed all patients by neck US and serum 
Tg at intervals of 3 or 6 months to examine whether there were any findings to indicate 
local recurrence. Either chest x-ray or CT scan was also performed once per year to detect 
potential lung metastases. Recurrence-free intervals were defined as the periods from the 
date of initial surgery to the date at which recurrence was diagnosed by neck US or CT plus 
cytological examination (when necessary).
This study was approved by the Institutional Review Board of Yonsei University College of 
Medicine.
Statistical analysis was performed using SPSS statistical software (version 23.0, SPSS, 
Chicago, IL, USA). Continuous, quantitative data are expressed as the mean±standard 
deviation, and categorical, qualitative data as frequencies and percentages. The 2 groups 
were compared using χ2 test, the Mann-Whitney U test, the Student's t test, or Fisher's exact 
test for qualitative or quantitative variables, as appropriate. For multivariate analysis for 
the risk factors for recurrence, multivariate logistic analysis and the Cox-hazard regression 
model were employed. The Kaplan-Meier method with log rank test was used to calculate 
survival rates between 2 groups. P values <0.05 were considered statistically significant.
RESULTS
The clinical characteristics of both groups are shown in Table 1. The 2 groups were well 
matched for age and sex ratio (P=NS). There were no significant differences in clinical 
findings between the 2 groups, except for number of retrieved and pathologically proven 
metastatic lateral LNs. The numbers of retrieved lateral LNs (30.5±11.9 vs. 25.4±9.6, 
P=0.045) and pathologically proven metastatic lateral LNs (5.4±4.5 vs. 4.8±3.6, P=0.001) 
were significantly greater in the MRND group. In addition, there no significant differences in 
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terms of tumor size, multiplicity, bilaterality, capsule invasion, and the central LN metastasis. 
Incidence of multiple-level LN metastases was higher in MRND group, and the distribution 
of metastasis LN levels was significantly different in both group.
The median follow up period were 94.3±37.6 months. During follow-up, local or distant 
recurrence developed in 84 patients, consisting of 57 (11.7%) in MRND and 27 (9.3%) in 
IJND group. The 10-year DFS was 88.3% for MRND and 90.3% for IJND group, and 15-year 
DFS was 88.0% in MRND and 89.5% in IJND group. The mean recurrence-free interval was 
44.1±33.6 months for MRND and 47.3±37.1 months for IJND group (P=0.694). No significant 
differences between the 2 groups were found regarding DFS (P=0.283) and recurrence rate 
(P=0.188) (Table 2).
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Table 1. Clinicopathologic characteristics of the 2 groups
Variables Total (n=778) MRND (n=489) IJND (n=289) P value
Age (yr) 0.141
<55 589 (75.7) 379 (77.5) 210 (72.7)
≥55 189 (24.3) 110 (22.5) 79 (27.3) 0.426
Sex
Female 615 (79.1) 385 (78.7) 230 (79.6)
Male 163 (21.0) 104 (21.3) 59 (20.4)
Retrieved central LNs(N) 7.6±5.6 7.7±5.7 7.5±5.6 0.247
Metastatic central LNs (N) 3.9±3.6 4.0±3.7 3.7±3.6 0.641
Retrieved lateral LNs (N) 28.6±11.4 30.5±11.9 25.4±9.6 0.045
Metastatic lateral LNs (N) 5.2±4.2 5.4±4.5 4.8±3.6 0.001
Tumor size (cm) 0.896
≤1 255 (32.8) 160 (32.7) 95 (32.9)
>1 and ≤2 329 (42.3) 205 (41.9) 124 (42.9)
>2 and ≤4 173 (22.2) 112 (22.9) 61 (21.1)
>4 21 (2.7) 12 (2.5) 9 (3.1)
Multiplicity 0.711
No 416 (53.5) 264 (54.0) 152 (52.6)
Yes 362 (46.5) 225 (46.0) 137 (47.4)
Bilaterality 0.157
No 518 (66.6) 335 (68.5) 183 (63.3)
Yes 260 (33.4) 154 (31.5) 106 (36.7)
Capsule invasion 0.045
No 145 (18.6) 102 (20.9) 43 (14.9)
Yes 633 (81.4) 387 (79.1) 246 (85.1)
Central LN metastasis 0.567
No 143 (18.4) 93 (19.0) 50 (17.3)
Yes 635 (81.6) 396 (81.0) 239 (82.7)
Distant metastases 27 (3.5) 14 (2.9) 13 (4.5) 0.480
Distribution of pathologic LLNs
Level 2 394 (50.1) 262 (53.5) 132 (45.7)
Level 3 589 (75.1) 361 (73.8) 228 (78.9)
Level 4 521 (66.3) 314 (64.2) 207 (71.6)
Level 5 96 (12.3) 96 (19.6) 0
Multiple-level LLN metastasis 0.004
No 223 (28.7) 133 (27.3) 90 (31.1)
Yes 555 (71.3) 356 (72.7) 199 (68.9)
Metastatic lymph node levels 0.006
1 level 223 (28.7) 133 (27.3) 90 (31.1)
2 levels 301 (38.7) 181 (37.1) 120 (41.5)
3 levels 226 (29.1) 148 (30.3) 78 (27.0)
4 levels 26 (3.3) 25 (5.1) 1 (0.3)
5 levels 1 (0.1) 1 (0.2) 0
MRND = modified radical neck dissection; IJND = internal jugular node dissection; LN = lymph node; LLN = lateral 
lymph node.
The risk factors for recurrence were evaluated using univariate and multivariate logistic 
regression analyses for all study populations. The univariate analysis showed that female 
gender, tumor size, capsule invasion, and multiple-level LLN metastasis were risk factors 
for recurrence, whereas age group divided by 55 years of age, operation method (MRND vs. 
IJND), multiplicity, bilaterality, and central LN metastasis were not significantly associated 
with recurrence. However, when these variables were included in multivariate logistic 
regression models, female gender, tumor size, and multiple-level LLN metastasis were 
risk factors for recurrence. The extent of LND, the main concern of this study, was not 
significantly associated with recurrence (Table 3).
In analysis of recurrence patterns, 7 patients in the MRND group had distant recurrence in 
lung and 55 patients had local recurrences that were mostly observed in level IV, followed 
by level III. In the IJND group, 7 patients had distant recurrence in lung and 1 patient died 
of simultaneous lung and bone recurrence. Twenty-four patients had local recurrences, the 
most common site being level IV, followed level III. There were 4 patients in MRND and 1 
patient in IJND diagnosed with recurrence in level V (Table 4).
Perioperative complications were compared between groups (Table 5). No significant 
differences in the frequency of complications were found. The incidence of permanent SAN 
injury was 0.8% in the MRND group and 0% in the IJND group.
DISCUSSION
Although lymphatic metastasis does not affect overall survival in PTC patients, there is a general 
consensus that cervical LN metastasis is the most significant prognostic factor for locoregional 
recurrences (22-24). This uncertainty of the prognostic impact of LN metastasis on overall survival 
and risk of postoperative morbidity after formal MRND contributes to the continuing debate 
about whether it is mandatory to dissect level V LNs in all PTC patients with lateral LN metastases.
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Table 2. The treatment outcomes of the 2 groups
Variables Total (n=778) MRND (n=489) IJND (n=289) P value
5-year disease free survival 95.9% 93.6% 90.9% 0.283
10-year disease free survival 91.8% 88.3% 90.3% 0.283
15-year disease free survival 89.2% 88.0% 89.5% 0.283
Recurrence rate 10.8% (84/778) 11.7% (57/489) 9.3% (27/289) 0.188
Recurrence-free intervals 45.2±34.6 44.1±33.6 47.3±37.1 0.694
MRND = modified radical neck dissection; IJND = internal jugular node dissection.
Table 3. Cox regression analysis of the relationship between clinicopathologic factors and recurrence
Variables Univariate analysis Multivariate analysis
OR (95% CI) P value OR (95% CI) P value
Age (yr):  ≥55 vs. <55 1.513 (0.957–2.391) 0.076
Sex: male vs. female 2.059 (1.313–3.229) 0.002 1.619 (1.015–2.583) 0.043
Operation method: MRND vs. IJND 0.779 (0.493–1.231) 0.284
Tumor size (continuous variable) 1.638 (1.433–1.873) 0.001 1.533 (1.329–1.769) 0.001
Multiplicity 1.312 (0.855–2.014) 0.213
Bilaterality 1.502 (0.973–2.318) 0.066
Capsule invasion 0.201 (1.012–4.034) 0.046 0.596 (0.297–1.196) 0.145
Central LN metastasis 0.998 (0.580–1.723) 0.920
Multiple-level LLN metastasis 1.904 (1.131–3.207) 0.015 1.596 (1.044–2.699) 0.041
OR = odds ratio; CI = confidence interval; LN = lymph node; LLN = lateral lymph node; MRND = modified radical 
neck dissection; IJND = internal jugular node dissection.
Dissection of level V is associated with postoperative morbidities, such as SAN dysfunction, 
that decrease patient's quality of life (QOL) postoperatively. The SAN must be identified and 
retracted to clear away LNs during the dissection of level V. Patten et al. (25) reported that 
most patients who underwent RND for head and neck cancer experienced pain, weakness, 
shoulder droop, and movement disability because the SAN had been sacrificed. Kupferman 
et al. (10) reported that even though the SAN preserved, postoperative shoulder dysfunction 
occurred in 27% of patients who underwent RND as a result of excessive retraction or 
ischemia. Also not to be underestimated is the impact on QOL that transection of the cervical 
rootlets incurs, often resulting in neck numbness or neuropathic pain (26). In our study, 
permanent SAN injuries were very rare events, with rates of 0% in group I and 1.2% in group 
II. This finding could be explained by all LND procedures having been performed by an 
experienced surgeon with a good anatomical knowledge of the SAN course.
Decision on the extent of LND, which is necessary for the treatment of regional metastases 
from PTC, should be based on predictable drainage patterns. The anterolateral group of 
nodes (level II, III and IV) is at the greatest risk of LNM, with level III nodes being the most 
frequently involved (27,28). In our previous study, we found that level IIb and V LNs were rarely 
metastasized and, therefore, did not necessarily require aggressive dissection. Preoperative 
nodal evaluation for LNM in PTC patients is essential in determining the inclusion of level V 
in a LND. Although the LNM could be detected by palpation (5), high resolution US has been 
widely used for preoperative nodal staging (29,30). Thereafter, the LNM was confirmed by 
FNAB for the node. In addition, the cystic LNM from PTC can be diagnosed by Tg measurement 
in the wash-out of needles used for FNAB (19). In our study, all patients who underwent 
LND underwent preoperative US staging to determine if clinically negative LN in level V. 
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Table 4. Distribution of recurrence in the 84 patients in 2 groups
Variables Total (n=84) MRND (n=57) IJND (n=27)
Local recurrence (single or multiple)
Total 79 (10.8%) 55 (11.7%) 24 (9.3%)
Recur side Ipsilateral 46 Contralateral 33 Ipsilateral 34 Contralateral 21 Ipsilateral 11 Contralateral 13
Level I 1 1
Level II 12 11 8 7 4 4
Level III 8 20 7 12 1 8
Level IV 13 23 8 16 5 7
Level V 3 2 2 2 1 0
Level VI 21 13 18 9 3 4
Level VII 4 1 4 0 0 1
Distant recurrence
Lung 14 7 7
Lung and bone 1 0 1
MRND = modified radical neck dissection; IJND = internal jugular node dissection.
Table 5. Comparison of perioperative complications in 2 groups
Complications Total MRND IJND P value
Transient hypocalcemia 285 (36.6) 185 (37.8) 100 (34.6) 0.397
Permanent hypocalcemia 43 (5.5) 29 (5.9) 14 (4.8) 0.627
Transient hoarseness 14 (1.8) 10 (2.0) 4 (1.4) 0.588
Permanent RLN injury 11 (1.4) 9 (1.8) 2 (0.3) 0.227
Chyle leakage 43 (5.5) 31 (6.3) 12 (4.2) 0.255
Hematoma 8 (1.0) 4 (0.8) 4 (1.4) 0.478
Seroma 72 (9.3) 49 (10.0) 23 (8.0) 0.372
Permanent SAN injury 4 (0.5) 4 (0.8) 0 0.485
Hornor syndrome 4 (0.5) 3 (0.6) 1 (0.3) 0.525
Infection 3 (0.4) 3 (0.6) 0 0.299
MRND = modified radical neck dissection; IJND = internal jugular node dissection; RLN = recurrent laryngeal nerve; SAN = spinal accessory nerve.
Consequently, we found that the frequency of LNM for level II and V and the presence of multi-
level LNM were significantly higher in the MRND group than the IJND group, suggesting our 
strategy of the LND based on preoperative nodal evaluation using US could be justified.
Currently, for PTC patients with LLN metastasis, most surgeons prefer formal MRND (level II–
V) to gain local control because some studies have demonstrated that high metastatic rates 
in level V nodes from 25% to 60% (11,13,27). On the other hand, in several recent studies, 
authors have recommended a selective approach to LND in PTC patients with LNM. Turanli 
(12) reported in a comparative study of 61 patients who underwent SND or MRND that the 
type of dissection was not related to DFS, overall survival, and local recurrence. Kandil et 
al. (31) reported that extensive neck dissection such as MRND among PTC patients did not 
result in an improved survival benefit compared with no LN dissection or SND. Caron et 
al. (13) reported that recurrence at levels I and V were uncommon in 106 PTC patients with 
LNM. They concluded that levels I and V did not require resection unless there is clinical or 
radiological evidence of disease. Our data regarding treatment outcomes correspond with 
these previous studies (12,31), suggesting that there was no difference between IJND and 
MRND groups regarding DFS and recurrence rate. Furthermore, multivariate analysis of 
this study revealed that the type of LND was not significantly associated with recurrence, 
and female gender, tumor size, and multiple-level LLN metastasis were independent risk 
factors for recurrence. Our findings indicate that the local recurrence after complete nodal 
dissection regardless of the type of LND is still related to aggressive factors like tumor size 
and LLN metastasis levels, which are known to be important prognostic factors in PTC.
The local recurrence rate after LND was reported to be 8%–32% (12,22). The present study 
showed of recurrence rate of 10.8% (11.7% in the MRND group and 9.3% in the IJND group) 
in all the groups compared with previous studies. This reason is that the IJND (level II–IV) 
performed in this study apply the same comprehensive anatomic dissection as the MRND 
and harvesting metastases cleared all lymphatic tissue at each level. Therefore, our results 
showed a significant reduction in the rate of recurrence. At our institute, a berry-picking 
procedure is not accepted for the surgical treatment of PTC nodal metastases, because it 
was reported to increase death rates due to recurrence in PTC patients (32).
In assessing recurrence at level V in patients who underwent IJND without level V, our 
results, which are in accordance with those of the study by Caron and Clark (6) that showed 
5 recurrence of total at level V, revealed that only 1 recurrence in level V occurred in the 
IJND group. The present study may be confronted with debate over the possibility of 
existence of occult level-V metastases in the IJND group, because Roh et al. (33) reported 
metastases detected only on postoperative pathological examination (pN1b) were present 
in a number of level–V specimens (16%–20%). Furthermore, recent studies to identify 
predictors of level V LLN metastasis demonstrated that simultaneous metastases to level II, 
III and IV, tumor multifocality, perineural invasion, and macroscopic extranodal extension 
were significant predictors in PTC patients with nodal metastases (11,34,35). However, these 
studies could be criticized because of the lack of long-term outcomes according to the 
type of LND. On the other hand, there are data suggesting that occult LLN metastasis or 
recurrence does not affect overall survival in PTC patients. Ito et al. (36) reported that pN1b 
did not independently affect the cause specific survival of patients. Noguchi and Murakami 
(37) reported that at least 75% of patients with PTC have occult LN metastases, but only 
about 20% become clinically evident, which means pN1b rarely developed sufficiently to 
be evident. In addition to these studies, our data support that patients with a clinically 
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negative level-V LN, although they might have occult LN metastases, would be expected to 
have lower recurrence rate.
This study has several limitations. First, the patient group divided not from the randomized 
control design but the operation method already performed and the study could have 
some inevitable features. Even though the clinicopathologic characteristics were not 
markedly different between the 2 groups, the IJND was performed on selected patients. 
Second, due to the long-term period of data enrollment, different radiologists and 
surgeons were involved in the evaluation and management of patients, resulting in 
possible inter-observer variability in the interpretation of metastasis.
Despite these limitations, our study had several strong points. First, this study has a 
relatively long-term follow-up period. Second, 778 cases of N1b patients were analyzed, 
which makes it a large study regarding the extent of lateral neck dissection.
In conclusion, IJND achieves favorable postoperative results in PTC with lateral neck node 
metastasis patients, and level V metastasis and recurrence incidence was low. Therefore, 
the extent of lateral neck node dissection, whether IJND or MRND, can be considered for 
patients according to the simultaneous metastasis level and the tumor size.
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